Metformin for the Prevention of Episodic Migraine (MPEM)

Completed · Phase 3 · Has a placebo group

Conditions studied: Migraine

In brief

The investigators will evaluate the safety and efficacy of metformin for preventive treatment of migraine in a randomized, double-blind, placebo-controlled, crossover trial.

Key facts

Study ID

NCT02593097

Run by

Mayo Clinic

People needed

34

Starts

2016-02-01

Expected to finish

2019-06-01

Last updated by the study team

2020-07-01

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• age 18-65 years
• a diagnosis of migraine with or without aura for >1 year according to the International Classification of Headache Disorders-IIIb

You may not qualify if…

• a diagnosis of diabetes mellitus or polycystic ovarian syndrome
• overuse of acute migraine treatments
• failure to respond to 3 or more classes of preventive drug treatments
• change in dose of migraine-preventive medication within 2 months of beginning the baseline diary phase
• significant somatic or psychiatric disease
• known alcohol or other substance abuse
• pregnant or breastfeeding.

Where it is running

• Mayo Clinic in Arizona — Scottsdale, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.